TY - JOUR T1 - Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00894-2020 VL - 55 IS - 6 SP - 2000894 AU - Amornpun Wongkarnjana AU - Christopher J. Ryerson Y1 - 2020/06/01 UR - http://erj.ersjournals.com/content/55/6/2000894.abstract N2 - The concept behind the INBUILD clinical trial was simple: if nintedanib slows progression of idiopathic pulmonary fibrosis (IPF) [1], then it might also slow progression in other forms of fibrotic interstitial lung disease (ILD) [2]. This was recently shown to be the case [3], with nintedanib slowing the rate of ILD progression in a diverse cohort of patients without IPF who met specific criteria for recent worsening. This study was a major advance, identifying a new treatment for a group of patients who previously had limited options.The criteria used to define progressive fibrosing interstitial lung disease identify a rapidly progressive phenotype that behaves like idiopathic pulmonary fibrosis, regardless of the underlying diagnosis https://bit.ly/3bW5DIV ER -